Kymera Therapeutics, Inc. (KYMR)
| Market Cap | 3.17B |
| Revenue (ttm) | 58.89M |
| Net Income (ttm) | -240.88M |
| Shares Out | 70.16M |
| EPS (ttm) | -3.11 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 615,914 |
| Open | 45.14 |
| Previous Close | 45.18 |
| Day's Range | 43.56 - 45.38 |
| 52-Week Range | 19.45 - 53.27 |
| Beta | 2.19 |
| Analysts | Strong Buy |
| Price Target | 58.94 (+30.37%) |
| Earnings Date | Aug 6, 2025 |
About KYMR
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis. The company also develops STAT6, a type 2 inflammation in allergic and atopic diseases; and TYK2 to treat aut... [Read more]
Financial Performance
In 2024, Kymera Therapeutics's revenue was $47.07 million, a decrease of -40.11% compared to the previous year's $78.59 million. Losses were -$223.86 million, 52.3% more than in 2023.
Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for KYMR stock is "Strong Buy." The 12-month stock price target is $58.94, which is an increase of 30.37% from the latest price.
News
Kymera Therapeutics Announces Pricing of $250 Million Public Offering
WATERTOWN, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines...
Kymera Therapeutics Announces Proposed Public Offering
WATERTOWN, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines...
Gilead signs up to $750 million cancer drug deal with Kymera Therapeutics
Gilead Sciences has entered into an option and license deal with Kymera Therapeutics to support the development and sales of a class of cancer drugs, the companies said on Wednesday.
Kymera Therapeutics Announces Sanofi IRAK4 Collaboration Update
Sanofi to advance Kymera's next-generation oral IRAK4 degrader development candidate, KT-485, into clinical testing and will not advance KT-474
Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders
FOSTER CITY, Calif. & WATERTOWN, Mass.--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ: GILD) and Kymera Therapeutics, Inc. (NASDAQ: KYMR), today announced that they have entered into an exclusive opt...
Wall Street Shows Love for Kymera Stock After Biotech's Promising Drug Trial
Shares of the biotech Kymera Therapeutics are up 50% since Monday.
Kymera: Positive Phase 1 KT-621 Study Leads To Q4 2025 AD Treatment Data
Kymera Therapeutics' KT-621 demonstrated strong proof-of-concept as an oral STAT6 degrader, showing biologic-like efficacy in phase 1 healthy volunteer data. Results from phase 1b BroADen study, using...
Kymera Stock Jumps. New Dermatitis Pill Could Challenge Regeneron Blockbuster.
Its dermatitis drug could win at least 10% of annual sales in dermatitis by 2030—or about $3 billion.
Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader
Phase 1 healthy volunteer data of KT-621, a once-a-day STAT6 degrader, surpass Kymera's target product profile, significantly derisking program and further validating its oral, biologics-like profile
Kymera Therapeutics to Announce KT-621 Phase 1 Healthy Volunteer Trial Results on June 2, 2025
Company to host video webcast at 8:00 a.m. ET on Monday, June 2, 2025 Company to host video webcast at 8:00 a.m. ET on Monday, June 2, 2025
Kymera Therapeutics to Participate in Upcoming June Investor Conferences
WATERTOWN, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines ...
Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the American Thoracic Society International Conference
KT-621, a potent, selective, oral STAT6 degrader, demonstrated comparable or superior activity to dupilumab in a newly disclosed preclinical chronic asthma model reversing disease progression
Kymera Therapeutics: Intriguing Degradation Thesis, But A Bit Powder Puff
I'm downgrading Kymera to 'Hold' due to slow clinical progress, pipeline uncertainty, and lack of near-term catalysts despite strong cash position. Kymera's unique focus on immunology with oral protei...
Kymera Therapeutics, Inc. (KYMR) Q1 2025 Earnings Call Transcript
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2025 Earnings Conference Call May 9, 2025 10:00 AM ET Company Participants Justine Koenigsberg - Vice President of Investor Relations Nello Mainolfi - Found...
Kymera Therapeutics Expands Industry Leading Immunology Pipeline with New First-in-Class, Oral IRF5 Degrader Program with Potential to Address Multiple Immuno-Inflammatory Diseases
IRF5 program strengthens Kymera's oral immunology pipeline with a complementary mechanism to expand into rheumatic and other autoimmune diseases with a potential best-in-class oral drug
Kymera Therapeutics Announces First Quarter 2025 Financial Results and Provides a Business Update
Completed KT-621 (STAT6) SAD/MAD Phase 1 healthy volunteer trial with data to be reported in June 2025 First patient dosed in KT-621 (STAT6) BroADen Phase 1b trial in moderate to severe atopic dermati...
Kymera Therapeutics to Participate in Fireside Chat at the BofA Securities 2025 Health Care Conference
WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines ...
Kymera Therapeutics Announces First Patient Dosed in BROADEN Phase 1b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader
Data from the BroADen Phase 1b atopic dermatitis (AD) patient trial expected to be reported in 4Q25 Completed SAD/MAD dosing in KT-621 Phase 1 healthy volunteer trial with data to be reported in June ...
Kymera Therapeutics Appoints Noah Goodman as Chief Business Officer
WATERTOWN, Mass., April 09, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicine...
Kymera Therapeutics, Inc. (KYMR) Q4 2024 Earnings Call Transcript
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Justine Koenigsberg - Vice President-Investor Relations Nello Mainolfi - Fou...
Kymera Therapeutics to Participate in Upcoming March Investor Conferences
WATERTOWN, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines...
Kymera Therapeutics to Participate in Upcoming February Investor Conferences
WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicin...
Kymera Therapeutics Outlines Key 2025 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs
KT-621 (STAT6) Phase 1 healthy volunteer trial ongoing, with data expected in 2Q25 Kymera plans to initiate a KT-621 Phase 1b trial in atopic dermatitis (AD) patients in 2Q25 with data in 4Q25 and pla...
Kymera Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14
WATERTOWN, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines...
Kymera: Protein Degradation Could Drive Dupixent-Like Value
Kymera Therapeutics' KT-474, partnered with Sanofi, is in Phase 2 trials for Hidradenitis Suppurativa and Atopic Dermatitis, with completion of studies expected mid-2026. KT-621, a STAT6 degrader for ...